Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014
Sankar A, Everhart A, Jena A, Jeffery M, Ross J, Shah N, Karaca-Mandic P. Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014. The Joint Commission Journal On Quality And Patient Safety 2023, 49: 458-466. PMID: 37380503, DOI: 10.1016/j.jcjq.2023.05.003.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseFDA safety communicationPhysician characteristicsLabel prescribingCare physiciansTestosterone prescribingService administrative claims dataNon-primary care physiciansCertain physician characteristicsDrug Administration (FDA) safety communicationPrimary care physiciansAdministrative claims dataCase mix indexTestosterone therapyArtery diseaseTestosterone prescriptionsPrescribing levelsMean agePrescription trendsTeaching hospitalClaims dataPrescription levelsMedicare feePrescribingUS Food
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply